Anavex Life Sciences Corp., ("Anavex", OTCBB: AVXL) has announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company's lead compound for Alzheimer's disease. "We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date", said Dr. Ozkan Yalkinoglou, Medical Director of ABX-CRO... 
More...
More...